Fig. 3: Adverse events reported at Visit 2 and at Visit 3.

The percentage of reported adverse events was significantly lower in the PCRS group than the NG at Visit 2. The percentage of reported adverse events did not significantly differ between groups at Visit 3. PCRS Placebo Control Reminder Script, NG Non-intervention Group.